We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Novavax Initiates Phase 1/2 Clinical Trial of COVID-19 Vaccine

By HospiMedica International staff writers
Posted on 27 May 2020
Print article
Illustration
Illustration
Novavax, Inc. (Gaithersburg, MD, USA) has begun enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVX‑CoV2373, a stable, prefusion protein made using its proprietary nanoparticle technology.

NVX‑CoV2373 includes Novavax’ proprietary Matrix‑M adjuvant to enhance immune responses and stimulate high levels of neutralizing antibodies. Novavax identified NVX‑CoV2373 as its lead SARS-CoV-2 candidate following pre-clinical testing that demonstrated high immunogenicity and high levels of neutralizing antibodies. These results provide strong evidence that the vaccine candidate will be highly immunogenic in humans, potentially leading to protection from COVID‑19 and thus helping to control the spread of this disease. Preliminary immunogenicity and safety results from the Phase 1 portion of the trial are expected in July 2020.

The Phase 1/2 clinical trial is being conducted in two parts. The Phase 1 portion is a randomized, observer-blinded, placebo-controlled trial designed to evaluate the immunogenicity and safety of NVX‑CoV2373, both adjuvanted with Matrix‑M and unadjuvanted. The trial is enrolling approximately 130 healthy participants 18 to 59 years of age at two sites in Australia. The protocol’s two-dose trial regimen assesses two dose sizes (5 and 25 micrograms) with Matrix‑M and without.

The Phase 2 portion is expected to be conducted in multiple countries, including the US, and would assess immunity, safety and COVID‑19 disease reduction in a broader age range. This Phase 1/2 approach allows for rapid advancement of NVX‑CoV2373 during the pandemic. The trial is being supported by the recently announced funding arrangement with the Coalition for Epidemic Preparedness Innovations (CEPI).

“Administering our vaccine in the first participants of this clinical trial is a significant achievement, bringing us one step closer toward addressing the fundamental need for a vaccine in the fight against the global COVID‑19 pandemic,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “We look forward to sharing the clinical results in July and, if promising, quickly initiating the Phase 2 portion of the trial.”

“Entering clinical trials is an important step on the path to delivering a safe, effective and globally accessible vaccine against COVID-19,” said Dr. Richard Hatchett, CEO of CEPI. “Vaccines provide our best hope of permanently defeating this pandemic, so it is encouraging to see rapid progress being made in the development of Novavax’ vaccine candidate. CEPI’s priority in building our portfolio has been to focus on vaccine candidates with the potential to be developed at speed and scale and made globally accessible. Our investment in Novavax allows us to focus on manufacturing in parallel with the clinical development of the vaccine, so that if the vaccine is proven to be safe and effective, we can make doses available to those who need them without delay.”

Related Links:
Novavax, Inc.

New
Gold Supplier
Creatinine Meter
StatSensor Xpress Creatinine Meter
New
Vital Signs Monitor
Aurus 20 A
New
Surgical Table
ARCUS 601
New
Eye Protector
Biliband

Print article

Channels

AI

view channel
Image: MyoVista Wavelet technology utilizes AI for early detection of heart disease (Photo courtesy of Heart Test Laboratories)

Novel ECG Technology Utilizes AI for Early Detection of Heart Disease

Cardiovascular disease is responsible for 17.9 million deaths every year, or about 32% of all deaths worldwide. Every week, millions of electrocardiographs (ECGs) are performed across the world, making... Read more

Critical Care

view channel
Image: Studies have shown the Autus Valve maintains control of blood flow as it expands (Photo courtesy of Boston Children’s Hospital)

Heart Valve That Grows Along With Child Could Reduce Invasive Surgeries

In children with congenital pulmonary valve disease, the flow of blood between the heart and lungs is impeded. In cases where the pulmonary valves have narrowed or are leaking and cannot be treated effectively... Read more

Surgical Techniques

view channel
Image: The LithoVue Elite System (Photo courtesy of Boston Scientific)

First Ever Ureteroscope System Monitors Intrarenal Pressure in Real-Time During Ureteroscopy Procedures

About one in 10 people can develop a kidney stone at some point in their lives. Ureteroscopy is commonly performed by urologists to diagnose and treat various problems in the urinary tract, particularly... Read more

Health IT

view channel
Image: Using digital data can improve health outcomes (Photo courtesy of Unsplash)

Electronic Health Records May Be Key to Improving Patient Care, Study Finds

When a patient gets transferred from a hospital to a nearby specialist or rehabilitation facility, it is often difficult for personnel at the new facility to access the patient’s electronic health records... Read more

Point of Care

view channel
Image: Steripath improves the diagnostic accuracy and timeliness of sepsis test results (Photo courtesy of Magnolia)

All-in-One Device Reduces False-Positive Diagnostic Test Results for Bloodstream Infections

Blood cultures are considered the gold standard diagnostic test for the detection of blood stream infections, such as sepsis. However, positive blood culture results can be frequently wrong, and about... Read more

Business

view channel
Image: The global patient positioning systems market is projected to reach USD 1.7 billion by 2027 (Photo courtesy of Pexels)

Global Patient Positioning Systems Market Driven by Increasing Chronic Diseases

The global patient positioning systems market is projected to grow at a CAGR of 4% from USD 1.4 billion in 2022 to USD 1.7 billion by 2027, driven by increasing technological advancements in medical devices,... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.